On November 29, 2013 the post of the day discussed Lemtrada, a new MS treatment that could allow patients to receive an IV five days one year, three the next and then possibly no other treatment to control multiple sclerosis. The trails were flawed in that the people knew they were on the medication causing the FDA to scratch their heads at the fantastic results and high risks.
On December 31, 2013 the FDA requested Genzyme to complete differently designed trails of Lemtrada. The drug’s serious side effects cannot be ignored despite the impressive results as an MS treatment. I suspect we have not seen the last of this tempting medication.
Information from Medicalnewstoday.com at: http://www.medicalnewstoday.com/releases/270696.php